PMID- 37169994 OWN - NLM STAT- MEDLINE DCOM- 20230515 LR - 20230525 IS - 1862-3514 (Electronic) VI - 18 IP - 1 DP - 2023 May 11 TI - Efficacy and safety of odanacatib for osteoporosis treatment: a systematic review and meta-analysis. PG - 67 LID - 10.1007/s11657-023-01261-7 [doi] AB - PURPOSE: Osteoporosis is a metabolic bone disease that commonly results in middle-aged and elderly people following fractures. Odanacatib (ODN), a potential osteoporosis medication, was stopped in the Long-term Odanacatib Fracture Trial (LOFT) phase III study because it increased the risk of stroke. Herein, we conducted a systematic review and meta-analysis to further assess the efficacy and safety of ODN in osteoporosis treatment. METHODS: We searched the PubMed, EMBASE, Cochrane Library, and Web of Science, using the core search terms "osteoporosis" and "odanacatib." The primary outcomes were the percentage change in markers of bone turnover and bone formation as well as that in the bone mineral density (BMD) of the lumbar spine, hip, femoral neck, and greater trochanter. The secondary outcome was the risk of adverse events (AEs), used to explore the safety of ODN. RESULTS: Ten articles-all double-blinded, randomized, placebo-controlled trials-were included. All trials were considered to be of high quality if they met the inclusion and exclusion criteria. We found that ODN increases BMD in the lumbar spine, total hip, and femoral neck, whereas it decreases the concentration of serum C-telopeptides of type I collagen (sCTx) and urinary N-telopeptide/creatinine ratio (uNTx/Cr). We found no significant differences in total, drug-related, serious, or skin AEs between the ODN and control groups. However, significant differences in fracture and stroke AEs were found between the ODN and control groups. CONCLUSION: ODN is an appealing long-term osteoporosis treatment method; however, further research should focus on the potential increased risk of fracture and stroke. CI - (c) 2023. International Osteoporosis Foundation and Bone Health and Osteoporosis Foundation. FAU - Chen, Rongjin AU - Chen R AD - Department of Orthopedics, Lanzhou University Second Hospital; Orthopedics Key Laboratory of Gansu Province; Orthopedics Clinical Research Center of Gansu Province, Lanzhou University Second Hospital, No. 82 Cuiyingmen, Chengguan District, Lanzhou, 730030, Gansu Province, China. FAU - Chen, Changshun AU - Chen C AD - Department of Orthopedics, Lanzhou University Second Hospital; Orthopedics Key Laboratory of Gansu Province; Orthopedics Clinical Research Center of Gansu Province, Lanzhou University Second Hospital, No. 82 Cuiyingmen, Chengguan District, Lanzhou, 730030, Gansu Province, China. FAU - Geng, Bin AU - Geng B AD - Department of Orthopedics, Lanzhou University Second Hospital; Orthopedics Key Laboratory of Gansu Province; Orthopedics Clinical Research Center of Gansu Province, Lanzhou University Second Hospital, No. 82 Cuiyingmen, Chengguan District, Lanzhou, 730030, Gansu Province, China. FAU - Yang, Chenhui AU - Yang C AD - Department of Orthopedics, Lanzhou University Second Hospital; Orthopedics Key Laboratory of Gansu Province; Orthopedics Clinical Research Center of Gansu Province, Lanzhou University Second Hospital, No. 82 Cuiyingmen, Chengguan District, Lanzhou, 730030, Gansu Province, China. FAU - Xiao, Hefang AU - Xiao H AD - Department of Orthopedics, Lanzhou University Second Hospital; Orthopedics Key Laboratory of Gansu Province; Orthopedics Clinical Research Center of Gansu Province, Lanzhou University Second Hospital, No. 82 Cuiyingmen, Chengguan District, Lanzhou, 730030, Gansu Province, China. FAU - Yang, Fei AU - Yang F AD - Department of Orthopedics, Lanzhou University Second Hospital; Orthopedics Key Laboratory of Gansu Province; Orthopedics Clinical Research Center of Gansu Province, Lanzhou University Second Hospital, No. 82 Cuiyingmen, Chengguan District, Lanzhou, 730030, Gansu Province, China. FAU - Wang, Hao AU - Wang H AD - Department of Orthopedics, Lanzhou University Second Hospital; Orthopedics Key Laboratory of Gansu Province; Orthopedics Clinical Research Center of Gansu Province, Lanzhou University Second Hospital, No. 82 Cuiyingmen, Chengguan District, Lanzhou, 730030, Gansu Province, China. FAU - Xia, Yayi AU - Xia Y AD - Department of Orthopedics, Lanzhou University Second Hospital; Orthopedics Key Laboratory of Gansu Province; Orthopedics Clinical Research Center of Gansu Province, Lanzhou University Second Hospital, No. 82 Cuiyingmen, Chengguan District, Lanzhou, 730030, Gansu Province, China. xiayy@lzu.edu.cn. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Review PT - Systematic Review DEP - 20230511 PL - England TA - Arch Osteoporos JT - Archives of osteoporosis JID - 101318988 RN - N673F6W2VH (odanacatib) RN - 0 (Bone Density Conservation Agents) SB - IM MH - Aged MH - Female MH - Middle Aged MH - Humans MH - *Bone Density Conservation Agents/adverse effects MH - *Osteoporosis, Postmenopausal/drug therapy MH - Double-Blind Method MH - *Osteoporosis/complications MH - Bone Density MH - *Fractures, Bone/complications MH - *Stroke/drug therapy/complications OTO - NOTNLM OT - Bone mineral density OT - Elderly OT - Randomized controlled trials OT - Serum N-terminal propeptide of type I collagen OT - Urinary N-telopeptide/creatinine ratio (uNTx/Cr) EDAT- 2023/05/12 01:07 MHDA- 2023/05/15 06:41 CRDT- 2023/05/11 23:29 PHST- 2023/01/09 00:00 [received] PHST- 2023/04/28 00:00 [accepted] PHST- 2023/05/15 06:41 [medline] PHST- 2023/05/12 01:07 [pubmed] PHST- 2023/05/11 23:29 [entrez] AID - 10.1007/s11657-023-01261-7 [pii] AID - 10.1007/s11657-023-01261-7 [doi] PST - epublish SO - Arch Osteoporos. 2023 May 11;18(1):67. doi: 10.1007/s11657-023-01261-7.